Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04886063 · ClinicalTrials.gov registry record · Phase 2
Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease
A Phase 2 study, sponsored by LeonaBio.
- Terminated
- Registry status
- Phase 2
- Development phase
- 423
- Enrollment target
NCT04886063: Clinical Trial Phase 2 study, sponsored by LeonaBio.
NCT04886063 is a Phase 2 study that was terminated before completion, run by LeonaBio. The registered enrollment target is 423 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (218% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04886063, a Phase 2 study, was terminated before completion, sponsored by LeonaBio.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 423 participants
- Enrollment target
Study Summary
The objective of this study is to determine the safety and tolerability of fosgonimeton (ATH-1017) in subjects with mild to moderate Alzheimer's disease who completed the 26-week randomized treatment in Study ATH-1017-AD-0201 or Study ATH-1017-AD-0202.
Primary Outcome
Description - To determine the safety and tolerability of ATH-1017 in subjects with mild to moderate Alzheimer's disease (AD) who completed the 26-week randomized treatment in Study ATH-1017-AD-0201 or Study ATH-1017-AD-0202
Interventions
- DRUG ATH-1017
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 423 participants |
| Start Date | 2021-06-30 |
| Est. Completion | 2024-10-23 |
| Phase | Phase 2 |
Why NCT04886063 stopped before completion
NCT04886063 is an interventional study that assigns participants to a tested intervention. The registered 423 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (218% higher).
The record links to 0 conditions, and to 1 intervention - of which ATH-1017 is the first listed.
NCT04886063 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04886063 about?
NCT04886063 is a clinical study titled "Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease". The objective of this study is to determine the safety and tolerability of fosgonimeton (ATH-1017) in subjects with mild to moderate Alzheimer's disease who completed the 26-week randomized treatment in Study ATH-1017-AD-0201 or Study ATH-1017-AD-0202.
What is the current status of trial NCT04886063?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 423 participants. The study started on 2021-06-30. Estimated completion is 2024-10-23.
What interventions are being tested in trial NCT04886063?
The interventions under investigation include: ATH-1017 (DRUG).
Who is sponsoring clinical trial NCT04886063?
This trial is sponsored by LeonaBio, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04886063's enrollment target sits among peer trials
423 91st of 2000 higher than 1,910 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06935591 · 423 participants · NA
Artificial Intelligence Mapping and Ablation of Non-Pulmonary Vein Electrical Drivers of AF Study
- NCT07128628 · 423 participants · Phase 2
A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease
- NCT05632770 · 424 participants · NA
A Deployment Focused Pragmatic Trial of Optimal Stepped Care Intervention Targeting PTSD and Comorbidity for Acutely Hospitalized Injury Survivors Treated in US Trauma Care Systems
- NCT05733767 · 424 participants · Phase 2
Smoking Cessation Pharmacotherapy-Nurse Practitioner Led Tobacco Treatment Team Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI